Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans
- 1 December 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 25 (12), 2470-2479
- https://doi.org/10.1161/01.atv.0000189309.05924.88
Abstract
The initiation, modulation, and resolution of thrombus associated with eroded or unstable coronary plaques are critically dependent on the efficacy of endogenous fibrinolysis. This is dependent on the cellular function of the surrounding endothelium and vascular wall. In particular, the acute release of tissue plasminogen activator from the endothelium makes an important contribution to the defense against intravascular thrombosis. Here, we describe the rationale and methodology for, and clinical relevance of, assessing acute endothelial tissue plasminogen activator release in humans. The investigation of endothelial fibrinolytic function has the potential to provide major new insights into the pathophysiology of cardiovascular disease, and to shape future therapeutic interventions.Keywords
This publication has 65 references indexed in Scilit:
- Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients Treated With Angiotensin-Converting Enzyme InhibitionHypertension, 2004
- Impaired Endothelial Release of Tissue-Type Plasminogen Activator in Patients With Chronic Kidney Disease and HypertensionHypertension, 2004
- Mortality in relation to smoking: 50 years' observations on male British doctorsBMJ, 2004
- Bradykinin Receptor Antagonism and Endothelial Tissue Plasminogen Activator Release in HumansArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- A murine model of myocardial microvascular thrombosisJournal of Clinical Investigation, 1999
- Vascular-Bed–Specific Hemostasis and Hypercoagulable StatesNew England Journal of Medicine, 1999
- Impaired capacity for endogenous fibrinolysis in essential hypertensionThe Lancet, 1998
- The predictability of risk factors with respect to incidence and mortality of myocardial infarction and total mortality. A 12‐year follow‐up of the Oslo Study, NorwayJournal of Internal Medicine, 1993
- Regulation of the Acute Release of Tissue‐type Plasminogen Activator from the Endothelium by Coagulation Activation ProductsAnnals of the New York Academy of Sciences, 1992
- Venous occlusion and chronic cigarette smoking: dose-dependent decrease in the measurable release of tissue-type plasminogen activator and von Willebrand factorAtherosclerosis, 1991